Yunnan Provincial Hospital of Traditional Chinese Medicine
Welcome,         Profile    Billing    Logout  
 59 Trials 
28 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ma, jun
NCT05353205: A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Recruiting
4
200
RoW
Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg)
Jiangsu Hansoh Pharmaceutical Co., Ltd.
CML, Chronic Phase
12/22
09/25
NCT06343935: A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Not yet recruiting
4
88
NA
Linperlisib, YY-20394
Shanghai YingLi Pharmaceutical Co. Ltd.
Indolent B-cell Lymphoma
04/24
04/25
NCT05367765: A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Not yet recruiting
4
2400
RoW
Flumatinib, Imatinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
CML, Chronic Phase
04/27
04/28
CONTINUUM, NCT03700476: Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Active, not recruiting
3
425
RoW
Sintilimab, IBI308, PD-1 antibody, Gemcitabine, Cisplatin, DDP, intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Innovent Biologics (Suzhou) Co. Ltd.
Nasopharyngeal Neoplasms
02/23
01/25
NCT06239727: Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Recruiting
3
593
RoW
PD-1 blocking antibody, Camrelizumab, Gemcitabine, GEM, Cisplatin (80 mg/m2), DDP, Reduced-dose Intensity-modulated radiotherapy, Reduced-dose IMRT, Conventional-dose Intensity-modulated radiotherapy, Conventional-dose IMRT, Cisplatin (100 mg/m2), Capecitabine
Sun Yat-sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
02/27
02/30
NCT06434467: The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

Not yet recruiting
3
83
RoW
Nelarabine injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma
12/25
05/26
NCT06514508: Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

Not yet recruiting
3
60
RoW
Motixafortide+G-CSF, BL-8040+G-CSF, Placebo+G-CSF
Guangzhou Gloria Biosciences Co., Ltd.
Multiple Myeloma
08/26
12/26
NCT06749899: QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Recruiting
3
580
RoW
QL1706, Gemcitabine, Cisplatin, Intensity-modulated radiotherapy
Sun Yat-sen University, Qilu Pharmaceutical Co., Ltd.
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
12/28
12/30
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

Recruiting
3
120
Europe, Canada, Japan, US, RoW
Depemokimab, Placebo
GlaxoSmithKline
Hypereosinophilic Syndrome
02/26
03/26
NCT03619824: PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma

Not yet recruiting
2
40
RoW
Sintilimab, IBI308, PD-1 antibody, Gemcitabine, Cisplatin, DDP, intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Innovent Biologics (Suzhou) Co. Ltd.
Nasopharyngeal Neoplasms
10/19
03/24
TQB2618-AK105-II-01, NCT05563480: TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Recruiting
2
90
RoW
TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection, Penpulimab injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection, TQB2618 injection; Penpulimab injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nasopharyngeal Carcinoma
10/23
05/24
PLATINUM, NCT03984357: Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

Active, not recruiting
2
152
RoW
PD-1 blocking antibody, PD-1 blockade, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Bristol-Myers Squibb
Nasopharyngeal Carcinoma
04/24
03/26
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma

Active, not recruiting
2
62
RoW
Rocbrutinib, NWP-775, LP-168
Guangzhou Lupeng Pharmaceutical Company LTD.
Mantle Cell Lymphoma (MCL)
12/24
12/25
STSP-0601-04, NCT06289166: Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Recruiting
2
25
RoW
STSP-0601 for Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hemophilia
02/25
02/25
ALTER-HN005, NCT05807880: Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma

Not yet recruiting
2
110
NA
The combination treatment of anlotinib, penpulimab and capecitabine.
Sun Yat-sen University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nasopharyngeal Neoplasms
10/24
10/25
NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Recruiting
1
108
RoW
MRG001
Shanghai Miracogen Inc.
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
10/22
10/23
NCT04991129: The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer

Recruiting
1
66
RoW
WJ01024
Suzhou Junjing BioSciences Co., Ltd.
Advanced Hematologic Malignancies, Advanced Solid Tumors
06/25
04/26
Li, Yi
NCT05058040: A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)

Active, not recruiting
4
2500
RoW
Sodium Oligomannate Capsules
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer Disease
01/25
04/25
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

Recruiting
4
1312
RoW
GV-971, Placebo
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer's Disease
06/29
12/29
NCT03236636: The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Recruiting
3
312
RoW
Icaritin, SNG-162, HUACHANSU PIAN, HUACHANSU PIAN（999）
Beijing Shenogen Biomedical Co., Ltd, Chinese Academy of Medical Sciences, NanJing PLA 81 Hospital, Peking University Cancer Hospital & Institute, Beijing Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Tumour Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Haikou People's Hospital, Fudan University, West China Hospital, Chongqing Traditional Chinese Medicine Hospital, Chifeng Municipal Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Zhengzhou University, Guilin Medical University, China, The Third Xiangya Hospital of Central South University, Yunnan Provincial Hospital of Traditional Chinese Medicine, The Sixth People's Hospital of Shenyang
Advanced HBV-Related Hepatocellular Carcinoma (HCC)
12/22
12/22
NCT04693351 / 2020-004653-69: Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Active, not recruiting
3
700
Europe, Canada, US, RoW
Troriluzole, Placebo
Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
04/25
04/25
GenTLE, NCT06063850: AMT-260 Gene Therapy Study in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy

Recruiting
1/2
12
US
AAV9-hSyn1-miGRIK2, AMT-260
UniQure Biopharma B.V.
Mesial Temporal Lobe Epilepsy
11/26
06/27
Chen, Qian
NCT03236636: The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Recruiting
3
312
RoW
Icaritin, SNG-162, HUACHANSU PIAN, HUACHANSU PIAN（999）
Beijing Shenogen Biomedical Co., Ltd, Chinese Academy of Medical Sciences, NanJing PLA 81 Hospital, Peking University Cancer Hospital & Institute, Beijing Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Tumour Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Haikou People's Hospital, Fudan University, West China Hospital, Chongqing Traditional Chinese Medicine Hospital, Chifeng Municipal Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Zhengzhou University, Guilin Medical University, China, The Third Xiangya Hospital of Central South University, Yunnan Provincial Hospital of Traditional Chinese Medicine, The Sixth People's Hospital of Shenyang
Advanced HBV-Related Hepatocellular Carcinoma (HCC)
12/22
12/22
NCT05173883: A Phase 1 Clinical Study of CU-20401 in Chinese Healthy Population

Completed
1
48
RoW
injection ，CU-20401, test group administration, injection ，placebo, Control group administration
Cutia Therapeutics（Wuxi）Co.,Ltd
Healthy Subjects
11/23
11/23
NCT05966701: The MAD Study of SSGJ-613 in Healthy Subjects

Not yet recruiting
1
36
RoW
SSGJ-613, Placebo
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Arthritis, Gouty
03/24
03/24
NCT06082323: A Single and Multiple Ascending Dose Trial of LT-002-158 in Healthy Adult Volunteers

Not yet recruiting
1
82
NA
LT-002-158/Placebo oral tablet(s), LT-002-158
Shanghai Leadingtac Pharmaceutical Co., Ltd.
Healthy Volunteer, Hidradenitis Suppurativa, Atopic Dermatitis
01/25
03/25
Ouyang, Xiaoyong
NCT06058546: Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis

Recruiting
2
180
RoW
Jiuweihuaban Pill placebo, Placebo group, low dose Jiuweihuaban Pill, Low dose group, high dose Jiuweihuaban Pill, High dose group
Tasly Pharmaceutical Group Co., Ltd
Plaque Psoriasis
10/25
10/25
Wen, Weibo
No trials found

Download Options